According to the latest market research report “Breast Cancer Liquid Biopsy Market (Biomarker – Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs), and Other Circulating Biomarkers; End-user – Hospitals and Physician Laboratories, Reference Laboratories, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2024” The global breast cancer liquid biopsy market was approximately worth USD 178 Million and is projected to reach a value of USD 642 Million with a CAGR of 20.9% over the forecast period of 2018-2024.
Speak to Analyst: https://www.infiniumglobalresearch.com/reports/enquiry/3386
The liquid biopsy in breast cancer is simple processes that enable the Traces of cancer’s DNA through a simple blood sample. It helps to collect a range of information that further helps to describe the most suitable treatment for the patients. This is a non-invasive alternative to surgical biopsies. Liquid biopsy test detects epidermal growth factor receptor (EGFR) gene mutations that assist doctors to choose the right treatment at the right time.
Breath cancer is the second largest cause of death worldwide. The rapidly growing demand for non-invasive cancer treatment and the growing prevalence of cancer are the major factors that drive the growth of the breast cancer market. In 2018, 2,093,876 cases of breast cancer were reported across the world. Thus, this is anticipated to boost the growth of breast cancer liquid biopsy market. Furthermore, the demand for non-invasive cancer treatments coupled with its advantages over the traditional treatments is favoring the market growth.
Download PDF Brochure: https://www.infiniumglobalresearch.com/reports/sample-request/3386
Breast Cancer Liquid Biopsy Industry: Segmentation
The global breasts cancer liquid biopsy market is segmented as a biomarker, and end-user. In terms of the biomarker, the breast cancer liquid biopsy market is categorized as extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and other circulating biomarkers. Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues that are secreted by the cancerous tumor. The extracellular vesicles (EVs) offers drug resistance, invasiveness and stemness across cancer cells, increased proliferation rate. It includes cancer-associated molecules such as glycoproteins, various non-coding RNAs and DNA fragments and mRNAs. Additionally, several countries have a strong government focus on healthcare costs and are implementing cost-effective health technology assessments that contribute to the growth of the extracellular vesicles (EVs) biomarkers in this market. By end users, the market classified into hospitals and physician laboratories, reference laboratories, and others.
Breast Cancer Liquid Biopsy Market: Regional Insights
Geographically, North America holds the maximum market share in the breasts cancer liquid biopsy market followed by Europe. High prevalence of breast cancer is the primary factor that drives the growth of North America breast cancer liquid biopsy market. According to the Breastcancer.org, in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer. In addition, the advancements in the cancer treatment, and developed healthcare infrastructure are contributing to breast cancer liquid biopsy market in this region. Moreover, Asia Pacific is the fastest growing region in the breast cancer liquid biopsy market.
View Detailed Table of Content here: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-breast-cancer-liquid-biopsy-market
Key Players in the Breast Cancer Liquid Biopsy Industry
The key companies in the global breast cancer liquid biopsy market include Isogen Life Science, GUARDANT HEALTH, INC, Biodesix, Inc., FLUXION BIOSCIENCES, Thermo Fisher Scientific Inc., Genomic Health, Cynvenio Biosystems, Inc., Illumina, Inc., Menarini Silicon Biosystems, and Myriad Genetics, Inc. among others. Major players in this market are focusing on the new product launch to enhance their product portfolio. For instance, Biocept, Inc. one of the leading commercial provider of liquid biopsy tests for ESR1 Biomarker Detection. This test is designed to offer physicians with clinically actionable information to advance the outcomes of patients diagnosed with cancer.
About Infinium Global Research
Infinium Global Research and Consulting Solutions is started with a single motto of being a business partner of the first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.
Infinium Global Research
Visit Our Website: https://www.infiniumglobalresearch.com